Motolese Francesco, Capone Fioravante, Magliozzi Alessandro, Vico Carlo, Iaccarino Gianmarco, Falato Emma, Pilato Fabio, Di Lazzaro Vincenzo
Department of Medicine and Surgery, Unit of Neurology, Neurophysiology, Neurobiology and Psichiatry, Università Campus Bio-Medico di Roma, Roma, Italy.
Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy.
Front Neurol. 2023 Jun 2;14:1176744. doi: 10.3389/fneur.2023.1176744. eCollection 2023.
Commercially available health devices are gaining momentum and represent a great opportunity for monitoring patients for prolonged periods. This study aimed at testing the feasibility of a smart device-based secondary prevention program in a cohort of patients with cryptogenic stroke.
In this proof-of-principle study, patients with non-disabling ischemic stroke and transient ischemic attacks (TIA) in the subacute phase were provided with a smartwatch and smart devices to monitor several parameters - i.e., oxygen saturation, blood pressure, steps a day, heart rate and heart rate variability - for a 4-week period (watch group). This group was compared with a standard-of-care group. Our primary endpoint was the compliance with the use of smart devices that was evaluated as the number of measures performed during the observation period.
In total, 161 patients were recruited, 87 in the WATCH group and 74 in the control group. In the WATCH group, more than 90% of patients recorded the ECG at least once a day. In total, 5,335 ECGs were recorded during the study. The median blood pressure value was 132/78 mmHg and the median oxygen saturation value was 97%. From a clinical standpoint, although not statistically significant, nine atrial fibrillation episodes (10.3%) in the WATCH group vs. 3 (4%) in the control group were detected.
Our study suggests that prevention programs for cerebrovascular disease may benefit from the implementation of new technologies.
市售健康设备正日益普及，为长期监测患者提供了巨大契机。本研究旨在测试基于智能设备的二级预防项目在隐源性卒中患者队列中的可行性。
在这项原理验证研究中，为亚急性期非致残性缺血性卒中和短暂性脑缺血发作（TIA）患者配备智能手表和智能设备，以监测多个参数，即血氧饱和度、血压、每日步数、心率和心率变异性，为期4周（手表组）。该组与标准治疗组进行比较。我们的主要终点是智能设备使用的依从性，通过观察期内所执行测量的数量来评估。
共招募了161名患者，手表组87名，对照组74名。在手表组中，超过90%的患者每天至少记录一次心电图。研究期间共记录了5335份心电图。血压中位数为132/78 mmHg，血氧饱和度中位数为97%。从临床角度来看，虽然无统计学意义，但手表组检测到9次房颤发作（10.3%），而对照组为3次（4%）。
我们的研究表明，脑血管疾病预防项目可能会从新技术的实施中受益。
